Tirzepatide Weight Loss: Fat Mass and Muscle Findings

Key points

• Tirzepatide was associated with nearly 16% mean weight loss over 24 weeks in adults with overweight or obesity.
• Fat mass decreased by 35.4%, while skeletal muscle mass remained relatively stable.
• BMI, waist circumference, waist-to-height ratio, fasting insulin, and HOMA-IR also improved.
• The findings come from real-world data and should be interpreted alongside the study’s retrospective design and accompanying diet and physical activity interventions.

Tirzepatide Reduces Fat Mass While Preserving Skeletal Muscle

A 24-week real-world study published in the Journal of Diabetes and Its Complications found that tirzepatide was associated with substantial weight and fat-mass reductions while maintaining skeletal muscle mass in adults with overweight or obesity.

Tirzepatide and body composition: What did the study find?

Obesity treatment involves more than reducing body weight. Changes in fat mass, skeletal muscle, and metabolic health can help clinicians assess the quality and potential clinical relevance of weight loss.

Researchers evaluated 122 adults treated at two centers in Palermo, Italy. Participants had overweight or obesity with at least one related condition, including prediabetes, hypertension, obstructive sleep apnea, dyslipidemia, or cardiovascular disease, but did not have type 2 diabetes.

Participants started tirzepatide at 2.5 mg once weekly and increased the dose to 5 mg after four weeks. They also followed a low-carbohydrate diet without prescribed calorie restriction and received tailored physical activity recommendations.

Researchers assessed body weight, BMI, waist circumference, waist-to-height ratio, fat mass, fat-free mass, and skeletal muscle mass at baseline, 12 weeks, and 24 weeks. Bioelectrical impedance analysis measured body composition.

Fat mass fell substantially while skeletal muscle remained stable

The results showed progressive weight loss throughout the 24 weeks. By week 24, 98% of participants lost at least 5% of their baseline body weight, 89% at least 10%, 72% at least 15%, and 59% at least 20%.

Mean reductions in BMI, waist circumference, and waist-to-height ratio reached 15.7%, 14.9%, and 15.2%, respectively.

Body composition findings were particularly notable. Fat mass decreased by 35.4% from baseline, while fat-free mass decreased by 5.1%. In contrast, skeletal muscle mass remained relatively stable during follow-up.

Metabolic measures also improved. Fasting insulin and HOMA-IR decreased over time, and changes in BMI, body weight, and fat mass showed positive associations with these measures of insulin resistance.

What does this mean for obesity care?

The findings suggest that tirzepatide and body composition deserve attention when evaluating weight-management outcomes. A substantial reduction in fat mass alongside relative preservation of skeletal muscle may provide a more informative picture than weight change alone.

However, clinicians should interpret these findings within the study’s limitations. The retrospective analysis had no control group, and participants also followed dietary and physical activity interventions. Therefore, the study cannot establish how much of the observed effect resulted specifically from tirzepatide.

The study also included predominantly women and used bioelectrical impedance analysis under routine clinical conditions. Longer-term research involving more diverse populations and controlled study designs will help clarify the durability of changes in fat mass, skeletal muscle, and metabolic health.

For More Updates, Explore all Endocrinology CME Conferences and Online Courses

For HCPs managing obesity, these findings reinforce the importance of looking beyond the number on the scale when assessing treatment response.

Source: 

Science Direct